- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06086418
Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery
Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Pediatric Ankle Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is proposed to explore the effect of systemic Dexamethasone on the duration of supraclavicular brachial plexus block for analgesia after pediatric ankle surgery.
After hand and wrist surgery, children need good analgesia. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe.
The safety of local anesthesia is essential in children due to the much lower toxicity threshold of local anesthetics. An effective adjuvant, such as Dexamethasone, could allow for a higher dilution of local anesthetics while maintaining and enhancing their analgesic effect.
There is considerable research where intravenous and perineural dexamethasone use has been compared in adults. However, there is a massive lack of research regarding children.
In this study, investigators compare different doses of perineural Dexamethasone. Groups 2 and 3 have dexamethasone doses of 0.1mg/kg and 0.05mg/kg added to local anesthetic.
The investigator's goal is to find a dexamethasone dose that is as low as possible but simultaneously covers the need for good pain relief and fast recovery postoperatively.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Małgorzata Domagalska, Ph.D.
- Phone Number: +48 608762068
- Email: m.domagalska@icloud.com
Study Contact Backup
- Name: Tomasz Kotwicki, Prof.dr hab.
Study Locations
-
-
Poznań
-
Poznan, Poznań, Poland, 61-701
- Recruiting
- Poznan University of Medical Sciences
-
Contact:
- Malgorzata Domagalska, Ph.D.
- Phone Number: 608762068
- Email: m.domagalska@icloud.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- children scheduled for hand/wrist surgery
- body weight > 5kg
Exclusion Criteria:
- infection at the site of the regional blockade
- coagulation disorders
- immunodeficiency
- ASA= or >4
- steroid medication in regular use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
0.2% ropivacaine for popliteal nerve block
|
administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the popliteal nerve block
Other Names:
|
Active Comparator: 0.1mg/kg Dexamethasone
0.1mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
|
administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the popliteal nerve block
Other Names:
|
Active Comparator: 0,05mg/kg dexamethasone
0.05mg/kg dexamethasone added to 0.2% ropivacaine for popliteal nerve block
|
administration of 0.5ml/kg of 0.2% ropivacaine with 0.05mg/kg Dexamethasone for the popliteal nerve block
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
first need of opiate
Time Frame: 48 hours
|
Time after surgery when the patient needs opiate for the first time
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid Consumption
Time Frame: 48 hours
|
Total opiate consumption after surgery
|
48 hours
|
Pain score
Time Frame: 4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery
|
children <3years old FLACC score (Face, Legs, Activity, Cry, Consolability) children >3years old NRS (Numerical Rating Scale)
|
4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery
|
NLR
Time Frame: 24 and 48 hours after surgery
|
Neutrophil-to-lymphocyte ratio
|
24 and 48 hours after surgery
|
PLR
Time Frame: 24 and 48 hours after surgery
|
Platelet-to-lymphocyte ratio
|
24 and 48 hours after surgery
|
Mobilisation
Time Frame: 4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery
|
Toe movement every 4 hours
|
4 hours, 8 hours, 12 hours, 16 hours, 18 hours, 24 hours, 28 hours, 32 hours, 36 hours, 40 hours, 44 hours, 48 hours after surgery
|
Blood glucose
Time Frame: 24 and 48 hours after surgery
|
Blood glucose every 24 hours during hospitalization
|
24 and 48 hours after surgery
|
Collaborators and Investigators
Investigators
- Study Director: Tomasz Kotwicki, Prof.dr hab., Poznan University of Medical Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Leg Injuries
- Musculoskeletal Diseases
- Wounds and Injuries
- Ankle Injuries
- Foot Diseases
- Foot Injuries
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
Other Study ID Numbers
- 13/2023
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Foot Diseases
-
NHS Greater Glasgow and ClydeUniversity of Central LancashireCompletedFoot Ankle Injuries | Foot Injury | Foot Deformity | Foot Sprain | Feet, FlatUnited Kingdom
-
Hacettepe UniversityEnrolling by invitationSpinal Curvatures | Flat Foot [Pes Planus] (Acquired), Left Foot | Flat Foot [Pes Planus] (Acquired), Right Foot | Flat Foot Acquired Bilateral (Pes Planus) | Pelvic ObliquityTurkey
-
Pamukkale UniversityCompletedFoot Deformities | Flatfoot | Foot; Deformity, Valgus, Congenital | Foot; Deformity, Valgus (Acquired)Turkey
-
Assiut UniversityUnknownFlat Foot; Rigid | Flat Foot; Spastic
-
Mustafa Kemal UniversityRecruitingFlat Foot [Pes Planus] (Acquired), Unspecified FootTurkey
-
Abant Izzet Baysal UniversityCompletedFlat Foot [Pes Planus] (Acquired), Unspecified FootTurkey
-
Dr Tim ExellPortsmouth Hospitals NHS Trust; Solent NHS TrustRecruitingFoot Drop, Unspecified FootUnited Kingdom
-
Muhammet Ayhan ORALCompletedDorsiflexion Deformity of FootTurkey
-
TOPMEDNatural Sciences and Engineering Research Council, Canada; Cryos Technologies...Active, not recruitingFlat Feet | High Arched FootCanada
-
LabrhaCompletedHallux Rigidus, Unspecified FootFrance
Clinical Trials on 0.9 % Sodium Chloride
-
University Hospital Birmingham NHS Foundation TrustUnknownCoronary Artery Bypass SurgeryUnited Kingdom
-
University of East AngliaUnknownVascular Diseases | Coronary Artery Disease | Diabetes Mellitus | Atherosclerosis | Cardiac DiseaseUnited Kingdom
-
Jeffrey Alan Klein, MDNot yet recruitingAnesthesia, Local | Injection Site Irritation | Injection Site Discomfort | Injection Site Bruising | Benzoic Acid Adverse ReactionUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedHepatic EncephalopathySpain
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
Oslo University HospitalUniversity of Oslo; Norwegian University of Science and Technology; St. Olavs... and other collaboratorsCompletedMyocardial Infarction | Coronary DiseaseNorway
-
University of EdinburghNHS LothianUnknown
-
Insel Gruppe AG, University Hospital BernRecruitingCritical Illness | Subarachnoid Hemorrhage | Sodium Disorder | Infusion FluidSwitzerland